Alzamend Neuro, Inc. (ALZN): Nasdaq/NYSE listing notice — Alzamend Neuro receives Nasdaq deficiency notice for stockholders' equity below $2.5M minimum

Alzamend Neuro, Inc.

Stockholders' equity reported at ~$2.2M as of Jan 31, 2026, below Nasdaq's $2.5M minimum requirement for continued listing.
Company has until May 4, 2026 to submit a plan to regain compliance; if accepted, Nasdaq may grant up to 180 days (to Sept 16, 2026).
Common stock continues trading on Nasdaq under symbol 'ALZN' with no immediate effect on listing.
Company is evaluating actions to regain compliance; no assurance plan will be accepted or compliance achieved.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.97

Alzamend Neuro, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

March 20, 2026, Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”) received a letter (the “ Letter ”) from the Listing Qualifications staff (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026 (the “ Form 10-Q ”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million. As reported on it

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Alzamend Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001214659-26-003620

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.